The Western Union Company (WU) and Mastercard (MA) have disclosed plans to strengthen their strategic partnership. Following the news, shares of Wester Union and Mastercard gained 1.5% and 2.6%, respectively.
With this deal, Mastercard Send will expand into Western Union’s global money movement network. The integration will allow beneficiaries of Western Union transfers in the U.S. to re-direct any U.S. domestic transaction to any debit card network within a few minutes. (See Western Union stock chart on TipRanks)
Further, Western Union customers across 16 European markets will be able to leverage Mastercard Send to send money transfers directly to their receiver’s Mastercard debit card.
The second integration involves Mastercard’s Cross-Border Services delivery via Western Union Business Solutions. This will help strengthen bank and trade network relationships. (See Mastercard stock chart on TipRanks)
Executives Commentary
Gabriella Fitzgerald, the President of Western Union’s business in the Americas region, said, “This is just one more example of the world’s leading financial services companies coming to Western Union for our technology, expertise and the power of our omni-channel global financial network to meet their cross-border money movement and payments needs.”
“Western Union is a critical partner for Mastercard as together we focus on digitizing and modernizing the movement of money — for consumers and businesses. Combined, our networks offer unique global reach, for efficient and secure transactions,” said Leigh Amaro, the Senior Vice-President of Enterprise Partnerships at Mastercard.
See Top Smart Score Stocks on TipRanks >>
Analyst Recommendation
Consensus among analysts is a Hold based on 1 Buy, 5 Holds and 2 Sells. The average Western Union price target of $21 implies upside potential of 14.9% to current levels.
Bloggers Remain Bullish
TipRanks data shows that financial blogger opinions are 100% Bullish on WU, compared to the sector average of 70%.
Related News:
Flux Posts Disappointing First Quarter Results
AstraZeneca Shares Drop Despite Q3 Earnings Beat
Biogen Gains 3.2% on Positive ADUHELM Phase 3 Data
